In order to understand if treatment with Rotenone, an inhibitor of complex I activity, might induce similar lysosomal alterations as observed in PARK2-PD fibroblasts, we treated NSC34 cells with this drug and we analyzed structural and functional changes in lysosomes. This evidence concerns the gene PRKN and Parkinson disease.